At the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, promising new data on drug combinations to treat metastatic melanoma was presented. The phase I and II trials focus on combining drugs to slow the development of resistance to drugs that inhibit BRAF, a gene that is mutated in about half of melanomas. Earlier trials with drugs that target BRAF generated excitement for their ability to quickly shrink melanoma tumors in suitable patients. ...Monday, 1 October 2012
For Melanoma Drug Combinations Effective: Study
At the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, promising new data on drug combinations to treat metastatic melanoma was presented. The phase I and II trials focus on combining drugs to slow the development of resistance to drugs that inhibit BRAF, a gene that is mutated in about half of melanomas. Earlier trials with drugs that target BRAF generated excitement for their ability to quickly shrink melanoma tumors in suitable patients. ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment